Studies in vivo and in vitro of serum amyloid P component in normals and in a patient with AA amyloidosis

Clinical and Experimental Immunology
Philip N HawkinsMark B Pepys

Abstract

Pure serum amyloid P component (SAP) was isolated from a normal donor pool, from individuals with the different genotypes of an MspI restriction fragment length polymorphism (RFLP) linked to the SAP gene, and from a patient with AA amyloidosis. The SAP preparations were all identical and all behaved as a single homogeneous species in polyacrylamide gel electrophoresis, isoelectric focussing, reverse-phase chromatography, binding in vitro to phosphoethanolamine-Sepharose (binding constant 2.4 x 10(7) l/mol) and AL amyloid fibrils (1.6 x 10(8) l/mol), and binding to amyloid deposits in vivo in mice with casein-induced amyloidosis. The in vivo metabolism of 125I-SAP from a single donor was normal and identical in three healthy individuals representing the three different MspI RFLP genotypes. There is thus no frequent polymorphism of SAP in normal subjects, and SAP altered with respect to the characteristics studied here is not a necessary condition for pathogenesis of systemic AA amyloidosis.

References

Jul 30, 1999·Nature Medicine·Mark B Pepys
Apr 28, 2006·Nature·Mark B PepysStephen P Wood
Nov 23, 2006·Proceedings of the National Academy of Sciences of the United States of America·Sandra B HaudekMark L Entman
Jul 1, 1995·European Journal of Nuclear Medicine·Philip N Hawkins, Mark B Pepys
Aug 2, 2014·Acta Crystallographica. Section D, Biological Crystallography·Simon E KolstoeStephen P Wood
Oct 28, 1998·Scandinavian Journal of Immunology·M NyboS E Svehag
May 17, 2000·FEBS Letters·A R CokerS P Wood
Dec 20, 2000·Proceedings of the National Academy of Sciences of the United States of America·M NoursadeghiMark B Pepys
Dec 30, 2009·Arthritis and Rheumatism·Francesco CarlucciMarina Botto
Oct 30, 2007·Journal of Medical Microbiology·Thomas P GrienerGlen D Armstrong
Apr 18, 2009·Proceedings of the National Academy of Sciences of the United States of America·Simon E KolstoeMark B Pepys
Jan 27, 1994·Nature·J EmsleyS P Wood
Mar 2, 2011·Journal of Molecular Recognition : JMR·Halina MikolajekStephen P Wood

Citations

Dec 1, 1990·The Journal of Clinical Investigation·Philip N HawkinsMark B Pepys
Apr 16, 1987·Biochimica Et Biophysica Acta·S MaudsleyMark B Pepys
Jan 1, 1988·International Archives of Allergy and Applied Immunology·B M KubakL A Potempa
Mar 1, 1988·The Journal of Experimental Medicine·Philip N HawkinsMark B Pepys
Oct 14, 1987·Biochemical and Biophysical Research Communications·Mark B Pepys, P J Butler
Sep 25, 1974·Journal of Chromatography·P G Righetti, J W Drysdale
Apr 1, 1968·The Journal of Clinical Investigation·M PrasE C Franklin
Aug 1, 1967·Proceedings of the Society for Experimental Biology and Medicine·E S CathcartA S Cohen
Sep 1, 1984·Scandinavian Journal of Immunology·J J Li, K P McAdam
Jan 1, 1982·Annals of the New York Academy of Sciences·J K Anderson, J E Mole
Jan 1, 1982·Annals of the New York Academy of Sciences·Mark B PepysA Feinstein
Jan 1, 1982·Annals of the New York Academy of Sciences·M L BaltzMark B Pepys
Jan 1, 1982·Journal of Immunological Methods·F C De Beer, Mark B Pepys

Related Concepts

Metabolic Process, Cellular
Gene Polymorphism
Casein allergenic extract
Amyloid fibril protein AL
In Vivo
Pathogenic Aspects
(125I)SAP-N3
Reactive Systemic Amyloidosis
Pathogenesis
Caseins

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Synapse Loss as Therapeutic Target in MS

As we age, the number of synapses present in the human brain starts to decline, but in neurodegenerative diseases this occurs at an accelerated rate. In MS, it has been shown that there is a reduction in synaptic density, which presents a potential target for treatment. Here is the latest research on synapse loss as a therapeutic target in MS.

Artificial Intelligence in Cardiac Imaging

Artificial intelligence (ai) techniques are increasingly applied to cardiovascular (cv) medicine in cardiac imaging analysis. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

Social Learning

Social learning involves learning new behaviors through observation, imitation and modeling. Follow this feed to stay up to date on the latest research.

Cell Atlas of the Human Eye

Constructing a cell atlas of the human eye will require transcriptomic and histologic analysis over the lifespan. This understanding will aid in the study of development and disease. Find the latest research pertaining to the Cell Atlas of the Human Eye here.

Single Cell Chromatin Profiling

Techniques like ATAC-seq and CUT&Tag have the potential to allow single cell profiling of chromatin accessibility, histones, and TFs. This will provide novel insight into cellular heterogeneity and cell states. Discover the latest research on single cell chromatin profiling here.

Genetic Screens in iPSC-derived Brain Cells

Genetic screening is a critical tool that can be employed to define and understand gene function and interaction. This feed focuses on genetic screens conducted using induced pluripotent stem cell (iPSC)-derived brain cells.